Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo.

Richmond JM, Strassner JP, Rashighi M, Agarwal P, Garg M, Essien KI, Pell LS, Harris JE.

J Invest Dermatol. 2019 Apr;139(4):769-778. doi: 10.1016/j.jid.2018.10.032. Epub 2018 Nov 10.

PMID:
30423329
2.

Vitiligo Pathogenesis and Emerging Treatments.

Rashighi M, Harris JE.

Dermatol Clin. 2017 Apr;35(2):257-265. doi: 10.1016/j.det.2016.11.014. Review.

3.

Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity.

Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE.

J Am Acad Dermatol. 2017 May;76(5):847-855.e5. doi: 10.1016/j.jaad.2016.12.021. Epub 2017 Mar 1.

4.

Sampling Serum in Patients With Vitiligo to Measure Disease Activity in the Skin.

Rashighi M, Harris JE.

JAMA Dermatol. 2016 Nov 1;152(11):1187-1188. doi: 10.1001/jamadermatol.2016.2501. No abstract available.

PMID:
27557448
5.

Serum chemokines herald disease activity and treatment response in vitiligo patients.

Rashighi M, Harris JE.

Br J Dermatol. 2016 Jun;174(6):1190-1. doi: 10.1111/bjd.14671. No abstract available.

PMID:
27317283
6.

Understanding autoimmunity of vitiligo and alopecia areata.

Rork JF, Rashighi M, Harris JE.

Curr Opin Pediatr. 2016 Aug;28(4):463-9. doi: 10.1097/MOP.0000000000000375. Review.

7.

Melanocytes in psoriasis: convicted culprit or bullied bystander?

Strassner JP, Rashighi M, Harris JE.

Pigment Cell Melanoma Res. 2016 May;29(3):261-3. doi: 10.1111/pcmr.12470. No abstract available.

8.

Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Rashighi M, Harris JE.

Ann Transl Med. 2015 Dec;3(21):343. doi: 10.3978/j.issn.2305-5839.2015.11.36. No abstract available.

9.

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).

Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J.

J Am Acad Dermatol. 2016 Feb;74(2):370-1. doi: 10.1016/j.jaad.2015.09.073. Epub 2015 Dec 11. No abstract available.

10.

Mesenchymal Stem Cells and Co-stimulation Blockade Enhance Bone Marrow Engraftment and Induce Immunological Tolerance.

Rajeshkumar B, Agrawal P, Rashighi M, Saidi RF.

Int J Organ Transplant Med. 2015;6(2):55-60.

11.

Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.

Agarwal P, Rashighi M, Essien KI, Richmond JM, Randall L, Pazoki-Toroudi H, Hunter CA, Harris JE.

J Invest Dermatol. 2015 Apr;135(4):1080-1088. doi: 10.1038/jid.2014.529. Epub 2014 Dec 18.

12.

CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris JE.

Sci Transl Med. 2014 Feb 12;6(223):223ra23. doi: 10.1126/scitranslmed.3007811.

13.

A network of high-mobility group box transcription factors programs innate interleukin-17 production.

Malhotra N, Narayan K, Cho OH, Sylvia KE, Yin C, Melichar H, Rashighi M, Lefebvre V, Harris JE, Berg LJ, Kang J; Immunological Genome Project Consortium.

Immunity. 2013 Apr 18;38(4):681-93. doi: 10.1016/j.immuni.2013.01.010. Epub 2013 Apr 4.

Supplemental Content

Loading ...
Support Center